Author

Jesus D Badillo

Observed name: Jesus Badillo

Institution: AbbVie (Germany)

Observed institution: AbbVie (Germany)

OpenAlex ID: A5039712440

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

2022 · Mohamed A Badawi, Benjamin Engelhardt, et al. · Blood · 2

Dose optimization and exposure-response analyses to support optimal dose of ABBV-400, a novel C-met–targeting antibody drug conjugate, in patients with metastatic colorectal cancer (mCRC).

2024 · Carla Biesdorf de Almeida, Benjamin Engelhardt, et al. · Journal of Clinical Oncology · 1

Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM).

2024 · Akshanth Polepally, Jesus D Badillo, et al. · Journal of Clinical Oncology

Works count: 3

Citation count: 3

H-index: 1

I10-index: